(Q46961022)

English

Pharmacodynamic monitoring of BAY 43-9006 (Sorafenib) in phase I clinical trials involving solid tumor and AML/MDS patients, using flow cytometry to monitor activation of the ERK pathway in peripheral blood cells

scientific article published in May 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/16498671

Pharmacodynamic monitoring of BAY 43-9006 (Sorafenib) in phase I clinical trials involving solid tumor and AML/MDS patients, using flow cytometry to monitor activation of the ERK pathway in peripheral blood cells (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/16498671

phase I clinical trial

0 references

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

object named as

David Hedley

3

0 references

author name string

Frances K Tong

1

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/16498671

Sue Chow

2

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/16498671

publication date

1 May 2006

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/16498671

Cytometry Part B: Clinical Cytometry

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/16498671

70

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/16498671

3

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/16498671

107-114

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/16498671

describes a project that uses

1 reference

based on heuristic

inferred from title

Whole blood fixation and permeabilization protocol with red blood cell lysis for flow cytometry of intracellular phosphorylated epitopes in leukocyte subpopulations

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20092

21 January 2018

Growth factor signaling and resistance to cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20092

7 January 2021

based on heuristic

inferred from DOI database lookup

PI3K/Akt signalling pathway and cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20092

7 January 2021

based on heuristic

inferred from DOI database lookup

Apoptosis in cancer--implications for therapy

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20092

7 January 2021

based on heuristic

inferred from DOI database lookup

JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20092

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20092

7 January 2021

based on heuristic

inferred from DOI database lookup

Cell signaling and cancer

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20092

7 January 2021

based on heuristic

inferred from DOI database lookup

Role of MAP kinase in tumor progression and invasion

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20092

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib--a novel targeted approach to treating cancer

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20092

7 January 2021

based on heuristic

inferred from DOI database lookup

Targeting the mitogen-activated protein kinase cascade to treat cancer

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20092

7 January 2021

based on heuristic

inferred from DOI database lookup

Opportunities and challenges in the development of kinase inhibitor therapy for cancer

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20092

7 January 2021

based on heuristic

inferred from DOI database lookup

Discovery of a novel Raf kinase inhibitor

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20092

7 January 2021

based on heuristic

inferred from DOI database lookup

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20092

7 January 2021

based on heuristic

inferred from DOI database lookup

Measurement of MAP kinase activation by flow cytometry using phospho-specific antibodies to MEK and ERK: potential for pharmacodynamic monitoring of signal transduction inhibitors.

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20092

7 January 2021

based on heuristic

inferred from DOI database lookup

BAY 43-9006: early clinical data in patients with advanced solid malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20092

7 January 2021

based on heuristic

inferred from DOI database lookup

The Raf/MEK/ERK signal transduction cascade as a target for chemotherapeutic intervention in leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20092

7 January 2021

based on heuristic

inferred from DOI database lookup

Indirect induction of a clastogenic effect in epidermal cells by a tumor promoter.

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20092

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20092

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CYTO.B.20092

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/16498671

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/16498671

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46961022&oldid=2143969119"